Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory). T cells are infection fighting blood cells that can kill tumor cells. Axicabtagene ciloleucel consists of genetically modified T cells, modified to recognize CD-19, a protein on the surface of cancer cells. These CD-19-specific T cells may help the body's immune system identify and kill CD-19-posit

Trial Details

NCT ID
NCT05077527
Phase
PHASE1
Sponsor
AIDS Malignancy Consortium
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Axicabtagene Ciloleucel
  • Cyclophosphamide
  • Fludarabine
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Chicago, Illinois, United States|41.85003,-87.65005
  • New York, New York, United States|40.71427,-74.00597
  • The Bronx, New York, United States|40.84985,-73.86641
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Participant with age \>= 18 years at the time of consent. Because no dosing or adverse event data are currently available on the use of axicabtagen…
  • Participant is able to understand and willing to sign a written informed consent document before any study procedures
  • Participant must have R/R aggressive B-cell NHL of the following histologies:
  • Diffuse large B-cell lymphoma (DLBCL, including transformed from indolent histology)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →